Cargando…

Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI

The extracellular pH (pHe) of solid tumors is often acidic, as a consequence of the Warburg effect, and an altered metabolic state is often associated with malignancy. It has been shown that acidosis can promote tumor progression; thus, many therapeutic strategies have been adopted against tumor met...

Descripción completa

Detalles Bibliográficos
Autores principales: Jardim-Perassi, Bruna Victorasso, Irrera, Pietro, Lau, Justin Y. C., Budzevich, Mikalai, Whelan, Christopher J., Abrahams, Dominique, Ruiz, Epifanio, Ibrahim-Hashim, Arig, Damgaci Erturk, Sultan, Longo, Dario Livio, Pilon-Thomas, Shari A., Gillies, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836819/
https://www.ncbi.nlm.nih.gov/pubmed/36704211
http://dx.doi.org/10.1155/2023/1944970
_version_ 1784868943311142912
author Jardim-Perassi, Bruna Victorasso
Irrera, Pietro
Lau, Justin Y. C.
Budzevich, Mikalai
Whelan, Christopher J.
Abrahams, Dominique
Ruiz, Epifanio
Ibrahim-Hashim, Arig
Damgaci Erturk, Sultan
Longo, Dario Livio
Pilon-Thomas, Shari A.
Gillies, Robert J.
author_facet Jardim-Perassi, Bruna Victorasso
Irrera, Pietro
Lau, Justin Y. C.
Budzevich, Mikalai
Whelan, Christopher J.
Abrahams, Dominique
Ruiz, Epifanio
Ibrahim-Hashim, Arig
Damgaci Erturk, Sultan
Longo, Dario Livio
Pilon-Thomas, Shari A.
Gillies, Robert J.
author_sort Jardim-Perassi, Bruna Victorasso
collection PubMed
description The extracellular pH (pHe) of solid tumors is often acidic, as a consequence of the Warburg effect, and an altered metabolic state is often associated with malignancy. It has been shown that acidosis can promote tumor progression; thus, many therapeutic strategies have been adopted against tumor metabolism; one of these involves alkalinization therapies to raise tumor pH to inhibit tumor progression, improve immune surveillance, and overcome resistance to chemotherapies. Chemical exchange saturation transfer-magnetic resonance imaging (CEST-MRI) is a noninvasive technique that can measure pH in vivo using pH-sensitive contrast agents. Iopamidol, an iodinated contrast agent, clinically used for computed tomography (CT), contains amide group protons with pH-dependent exchange rates that can reveal the pHe of the tumor microenvironment. In this study, we optimized intraperitoneal (IP) delivery of iopamidol to facilitate longitudinal assessments of orthotopic pancreatic tumor pHe by CEST-MRI. Following IV-infusion and IP-bolus injections, we compared the two protocols for assessing tumor pH. Time-resolved CT imaging was used to evaluate the uptake of iopamidol in the tumor, revealing that IP-bolus delivered a high amount of contrast agent 40 min postinjection, which was similar to the amounts reached with the IV-infusion protocol. As expected, both IP and IV injection protocols produced comparable measurements of tumor pHe, showing no statistically significant difference between groups (p=0.16). In addition, we showed the ability to conduct longitudinal monitoring of tumor pHe using CEST-MRI with the IP injection protocol, revealing a statistically significant increase in tumor pHe following bicarbonate administration (p < 0.001). In conclusion, this study shows the capability to measure pHe using an IP delivery of iopamidol into orthotopic pancreatic tumors, which is important to conduct longitudinal studies.
format Online
Article
Text
id pubmed-9836819
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-98368192023-01-25 Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI Jardim-Perassi, Bruna Victorasso Irrera, Pietro Lau, Justin Y. C. Budzevich, Mikalai Whelan, Christopher J. Abrahams, Dominique Ruiz, Epifanio Ibrahim-Hashim, Arig Damgaci Erturk, Sultan Longo, Dario Livio Pilon-Thomas, Shari A. Gillies, Robert J. Contrast Media Mol Imaging Research Article The extracellular pH (pHe) of solid tumors is often acidic, as a consequence of the Warburg effect, and an altered metabolic state is often associated with malignancy. It has been shown that acidosis can promote tumor progression; thus, many therapeutic strategies have been adopted against tumor metabolism; one of these involves alkalinization therapies to raise tumor pH to inhibit tumor progression, improve immune surveillance, and overcome resistance to chemotherapies. Chemical exchange saturation transfer-magnetic resonance imaging (CEST-MRI) is a noninvasive technique that can measure pH in vivo using pH-sensitive contrast agents. Iopamidol, an iodinated contrast agent, clinically used for computed tomography (CT), contains amide group protons with pH-dependent exchange rates that can reveal the pHe of the tumor microenvironment. In this study, we optimized intraperitoneal (IP) delivery of iopamidol to facilitate longitudinal assessments of orthotopic pancreatic tumor pHe by CEST-MRI. Following IV-infusion and IP-bolus injections, we compared the two protocols for assessing tumor pH. Time-resolved CT imaging was used to evaluate the uptake of iopamidol in the tumor, revealing that IP-bolus delivered a high amount of contrast agent 40 min postinjection, which was similar to the amounts reached with the IV-infusion protocol. As expected, both IP and IV injection protocols produced comparable measurements of tumor pHe, showing no statistically significant difference between groups (p=0.16). In addition, we showed the ability to conduct longitudinal monitoring of tumor pHe using CEST-MRI with the IP injection protocol, revealing a statistically significant increase in tumor pHe following bicarbonate administration (p < 0.001). In conclusion, this study shows the capability to measure pHe using an IP delivery of iopamidol into orthotopic pancreatic tumors, which is important to conduct longitudinal studies. Hindawi 2023-01-05 /pmc/articles/PMC9836819/ /pubmed/36704211 http://dx.doi.org/10.1155/2023/1944970 Text en Copyright © 2023 Bruna Victorasso Jardim-Perassi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jardim-Perassi, Bruna Victorasso
Irrera, Pietro
Lau, Justin Y. C.
Budzevich, Mikalai
Whelan, Christopher J.
Abrahams, Dominique
Ruiz, Epifanio
Ibrahim-Hashim, Arig
Damgaci Erturk, Sultan
Longo, Dario Livio
Pilon-Thomas, Shari A.
Gillies, Robert J.
Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI
title Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI
title_full Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI
title_fullStr Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI
title_full_unstemmed Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI
title_short Intraperitoneal Delivery of Iopamidol to Assess Extracellular pH of Orthotopic Pancreatic Tumor Model by CEST-MRI
title_sort intraperitoneal delivery of iopamidol to assess extracellular ph of orthotopic pancreatic tumor model by cest-mri
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9836819/
https://www.ncbi.nlm.nih.gov/pubmed/36704211
http://dx.doi.org/10.1155/2023/1944970
work_keys_str_mv AT jardimperassibrunavictorasso intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT irrerapietro intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT laujustinyc intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT budzevichmikalai intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT whelanchristopherj intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT abrahamsdominique intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT ruizepifanio intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT ibrahimhashimarig intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT damgacierturksultan intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT longodariolivio intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT pilonthomassharia intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri
AT gilliesrobertj intraperitonealdeliveryofiopamidoltoassessextracellularphoforthotopicpancreatictumormodelbycestmri